Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + lenvatinib + liposomal irinotecan in advanced esophageal squamous cell carcinoma after failure of first-line immunochemotherapy
ChiCTR2400088078Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, lenvatinib and irinotecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Objective response rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
tislelizumablenvatinibirinotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400088078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088078.